Dapagliflozin Completes Phase 3 and Meets Clinical Study Goals

Dapaglifozin is a once a day oral medication for people with type 2 diabetes. This medication falls into the group of diabetic medications known as SGLT2. This class of medications acts independently of insulin mechanisms. Meaning they assist the secretion of glucose and the related calories in urine, resulting in lower levels of glucose in the blood.

The Phase 3 Clinical Study Findings

The findings in the phase 3 clinical studies were just what researchers had hoped for. The majority of the diabetics in the 24-week study responded in a positive nature to the medication. 4 mg a day of dapaglifozin was able to improve the sugar levels in the body.

As with all medications of any kind for any disease, there was side effects the main side effect was an increase in genital tract infections. Genital tract infection is not the same as a urinary tract infection. Overall, the medication did just what researchers hoped it would do and that is always good news for any medication in a clinical study phase.

Source: Astra Zeneca